Short Interest in Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) Increases By 383.3%

Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY) saw a significant growth in short interest during the month of June. As of June 15th, there was short interest totalling 2,900 shares, a growth of 383.3% from the May 31st total of 600 shares. Based on an average daily trading volume, of 3,900 shares, the short-interest ratio is presently 0.7 days.

Santen Pharmaceutical Stock Performance

Shares of Santen Pharmaceutical stock traded down $0.12 during trading hours on Thursday, hitting $9.88. The company’s stock had a trading volume of 40,570 shares, compared to its average volume of 4,632. Santen Pharmaceutical has a twelve month low of $8.15 and a twelve month high of $10.85. The firm has a fifty day moving average of $10.06 and a 200-day moving average of $9.90.

Santen Pharmaceutical Company Profile

Santen Pharmaceutical Co, Ltd. engages in the research and development, manufacture, and marketing of pharmaceuticals and medical devices in Japan and internationally. Its product portfolio includes tafluprost/timolol maleate, a prostaglandin F2a derivative and a beta-adrenergic receptor blocker; and netarsudil mesilate and latanoprost, a prostaglandin F2a derivative which is marketing approval phase for the treatment of glaucoma and ocular hypertension.